Roland Berger: The Main Question in Life Sciences Consulting

Why It Matters

Prioritising funding for emerging therapies determines market leadership and patient outcomes in a rapidly evolving biotech landscape, guiding investors and executives toward high‑value opportunities.

Key Takeaways

• Identify highest‑impact areas: multiomics, CGT, rare disease treatments.
• Align scientific ambition with CFO, CEO, genetics, medical leadership.
• Translate strategic goals into decision‑grade funding choices quickly.
• Evaluate partnership options to accelerate AI‑enabled drug interpretation.
• Implement a disciplined roadmap to fund next‑gen medicines.

Summary

Roland Berger’s life‑sciences consulting team is helping a fast‑moving biotech client decide where to allocate capital as the industry races toward multi‑omics, cell‑and‑gene therapies, rare‑disease treatments and AI‑driven drug interpretation. The core question posed by the client – “what do we fund first and what do we not fund yet?” – forces a strategic triage of scientific ambition against financial reality.

The firm’s analysis prioritises three high‑impact domains: multi‑omics platforms, next‑generation cell‑and‑gene therapies (CGT) and AI‑enabled interpretation tools for rare diseases. By working directly with the CFO, CEO, chief genetics officer and chief medical officer, Berger translates lofty scientific goals into decision‑grade funding choices, defining clear partnership criteria and a timeline for investment.

A key illustration from the interview is the “200 kilometers per hour” pace of change, underscoring the urgency of disciplined decision‑making. The consultants stress that strategic direction, partner selection and immediate funding allocations must be aligned across the C‑suite and scientific leadership to avoid mis‑spending on lower‑impact projects.

The implication for the broader industry is clear: firms that embed cross‑functional governance and a rigorous funding roadmap will capture early‑stage market leadership in next‑gen therapeutics, while competitors risk lagging behind as the pace of innovation accelerates.

Original Description

Science + funding strategy = impact

Roland Berger's Elsy Dumit shares the key questions in life sciences consulting.

🎥 Highlight from the Life Sciences Consulting Panel

Watch the full panel discussion on the Management Consulted YouTube channel: https://www.youtube.com/watch?v=PbgEaZlphI4

#managementconsulted #rolandberger #lifesciences #science #strategy #impact #client #clinical

Subscribe to our channel: https://www.youtube.com/@Managementconsulted?sub_confirmation=1

Additional Resources

⚑ Learn how to use Excel and PowerPoint like a consultant with this course: https://managementconsulted.com/excel-powerpoint/?utm_campaign=20250416-present-like-a-consultant&utm_medium=social&utm_source=youtube

⚑ Get 1:1 Power Presentations Coaching to become a Trusted Advisor in your organization: https://managementconsulted.com/power-presentation/?utm_campaign=20250416-present-like-a-consultant&utm_medium=social&utm_source=youtube

⚑ Learn how Executive Communication Training could increase your team's influence: https://managementconsulted.com/storytelling/?utm_campaign=20250416-present-like-a-consultant&utm_medium=social&utm_source=youtube

Subscribe to our channel: https://www.youtube.com/@Managementconsulted?sub_confirmation=1